Stockreport

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024) Progr [Read more]